A New Therapy Offers A Different Approach to Inhibiting the Complement System

Cedric Francois, co-founder and CEO of Apellis, discusses the recent FDA approval of the PNH therapy Empaveli, what advantages it may provide over existing therapies, and other indications the company will pursue for this medicine.